Tizona

Tizona Therapeutics is a US immuno-oncology company. In 2019, Abbvie purchased an option to in-license Tizona’s most advanced clinical program for payments potentially totalling more than $1b. This program has now been spun out into Trishula Therapeutics. In 2020, Gilead purchased an option to acquire the remainder of Tizona for payments potentially totalling more than $1.5b, including $300m upfront.